CN105531275A - 用于cgrp受体拮抗剂的制剂 - Google Patents
用于cgrp受体拮抗剂的制剂 Download PDFInfo
- Publication number
- CN105531275A CN105531275A CN201480050553.6A CN201480050553A CN105531275A CN 105531275 A CN105531275 A CN 105531275A CN 201480050553 A CN201480050553 A CN 201480050553A CN 105531275 A CN105531275 A CN 105531275A
- Authority
- CN
- China
- Prior art keywords
- composition
- liquid medicine
- oxo
- pyridine
- vite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 74
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 2
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title description 4
- 239000007788 liquid Substances 0.000 claims abstract description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims description 53
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 12
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 12
- 229920001983 poloxamer Polymers 0.000 claims description 12
- 229960000502 poloxamer Drugs 0.000 claims description 12
- -1 diol ester Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004376 Sucralose Substances 0.000 claims description 6
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000012052 hydrophilic carrier Substances 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 244000178870 Lavandula angustifolia Species 0.000 claims description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 4
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 4
- 239000001102 lavandula vera Substances 0.000 claims description 4
- 235000018219 lavender Nutrition 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical group CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000003352 sequestering agent Substances 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 abstract description 23
- 208000019695 Migraine disease Diseases 0.000 abstract description 11
- 206010027599 migraine Diseases 0.000 abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 13
- 238000003756 stirring Methods 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 7
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 208000006561 Cluster Headache Diseases 0.000 description 5
- 208000018912 cluster headache syndrome Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 239000000120 Artificial Saliva Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039361 Sacroiliitis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 2
- 229960005164 acesulfame Drugs 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000036427 bronchial hyperreactivity Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- DDOOFTLHJSMHLN-ZQHRPCGSSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=CC=CC=C1 DDOOFTLHJSMHLN-ZQHRPCGSSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- CGDZXLJGHVKVIE-DNVCBOLYSA-N n-[(3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide Chemical compound FC1=CC=CC([C@H]2CN(CC(F)(F)F)C(=O)[C@H](NC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)=C1F CGDZXLJGHVKVIE-DNVCBOLYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- ITIXDWVDFFXNEG-JHOUSYSJSA-N olcegepant Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCN(CC1)C=1C=CN=CC=1)NC(=O)N1CCC(CC1)N1C(NC2=CC=CC=C2C1)=O)C1=CC(Br)=C(O)C(Br)=C1 ITIXDWVDFFXNEG-JHOUSYSJSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 229950002563 telcagepant Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229950001679 ubrogepant Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明涉及含有CGRP受体拮抗剂的液体药物组合物。本发明的CGRP受体拮抗剂液体药物组合物为不含醇的低体积的液体药物组合物,其可在不使用水的情况下服用以治疗偏头痛。
Description
发明背景
本发明涉及CGRP受体拮抗剂的液体药物组合物。
CGRP为一种强效的神经调节剂,其已经牵涉在脑血管病症诸如偏头痛和丛集性头痛的病理学中。在临床研究中发现在偏头痛发作过程中在颈静脉中出现CGRP的水平上升(Goadsby等人(1990)Ann.Neurol.28,183-187),CGRP的唾液水平在偏头痛受试者中在发作之间(Bellamy等人(2006)Headache46,24-33)及在发作过程中(Cady等人(2009)Headache49,1258-1266)是上升的,且已经显示CGRP本身能够触发偏头痛(Lassen等人(2002)Cephalalgia22,54-61)。在临床试验中已经显示CGRP受体拮抗剂BIBN4096BS可有效治疗偏头痛的急性发作(Olesen等人(2004)NewEngl.J.Med.350,1104-1110)且能够在对照组中预防由CGRP浸入所引起的头痛(Petersen等人(2005)Clin.Pharmacol.Ther.77,202-213)。还已经显示口服可生物利用的CGRP受体拮抗剂Telcagepant在III期临床试验中的抗偏头痛有效性(Ho等人(2008)Lancet372,2115-2123;Connor等人(2009)Neurology73,970-977)。
CGRP受体拮抗剂对于在人类和动物中且特别是在人类中涉及CGRP的病症而言可为有用的药理学药物。这样的病症包括偏头痛和丛集性头痛(Doods(2001)Curr.Opin.Invest.Drugs2,1261-1268;Edvinsson等人(1994)Cephalalgia14,320-327);慢性紧张型头痛(Ashina等人(2000)Neurology14,1335-1340);疼痛(Yu等人(1998)Eur.J.Pharmacol.347,275-282);慢性疼痛(Hulsebosch等人(2000)Pain86,163-175);神经源性炎症和炎性疼痛(Holzer(1988)Neuroscience24,739-768;Delay-Goyet等人(1992)ActaPhysiol.Scanda.146,537-538;Salmon等人(2001)NatureNeurosci.4,357-358);眼部疼痛(May等人(2002)Cephalalgia22,195-196)、牙痛(Awawdeh等人(2002)Int.Endocrin.J.35,30-36)、非胰岛素依赖性糖尿病(Molina等人(1990)Diabetes39,260-265);血管病症;炎症(Zhang等人(2001)Pain89,265);关节炎、支气管高反应性、哮喘(Foster等人(1992)Ann.NYAcad.Sci.657,397-404;Schini等人(1994)Am.J.Physiol.267,H2483-H2490;Zheng等人(1993)J.Virol.67,5786-5791);休克、败血病(Beer等人(2002)Crit.CareMed.30,1794-1798);鸦片戒断综合征(Salmon等人(2001)NatureNeurosci.4,357-358);吗啡耐受(Menard等人(1996)J.Neurosci.16,2342-2351);男性和女性中的热潮红(Chen等人(1993)Lancet342,49;Spetz等人(2001)J.Urology166,1720-1723);变应性皮炎(Wallengren(2000)ContactDermatitis43,137-143);银屑病;脑炎、脑外伤、局部缺血、中风、癫痫和神经变性疾病(Rohrenbeck等人(1999)Neurobiol.Dis.6,15-34);皮肤疾病(GeppettiandHolzer,Eds.,NeurogenicInflammation,1996,CRCPress,BocaRaton,FL)、神经性皮肤发红、皮肤发红(skinrosaceousness)和红斑;耳鸣(Herzog等人(2002)J.Membr.Biol.189,225);肥胖(Walker等人(2010)Endocrinology151,4257-4269);炎性肠病、肠易激综合征(Hoffman等人(2002)Scand.J.Gastroenterol.37,414-422)和膀胱炎。特别重要的是,急性或预防性处置包括偏头痛和丛集性头痛在内的头痛。
CGRP受体拮抗剂的代表性实例包括MerckSharp&DohmeCorp.的在2012年5月18日出版的国际公开文本WO2012/064910所公开的那些,将其全部内容通过引用的方式并入到本申请中。
CGRP受体拮抗剂可针对口服给药通过使用包括热熔融挤出和喷雾干燥在内的各种方法被配制为片剂。类似地,CGRP受体拮抗剂可针对口服给药被配制为明胶胶囊、软胶囊中的液体或硬胶囊中的干粉或半固体。另外,CGRP受体拮抗剂可针对静脉内给药来配制。
本发明的CGRP受体拮抗剂液体药物组合物为不含醇的低体积的液体药物组合物,其可在不使用水的情况下服用以治疗偏头痛。本发明的液体药物组合物与CGRP受体拮抗剂的其它液体组合物相比的优势在于在用唾液稀释后活性成分不会析出。另外,本发明的液体药物组合物具有治疗的快速起效。
发明内容
本发明涉及含有CGRP受体拮抗剂的液体药物组合物。本发明的CGRP受体拮抗剂液体药物组合物为不含醇的低体积的液体药物组合物,其可在不使用水的情况下服用以治疗偏头痛。本发明还公开了制备所述药物组合物的方法。
具体实施方式
本发明涉及含有CGRP受体拮抗剂的液体药物组合物。本发明的CGRP受体拮抗剂液体药物组合物包含CGRP受体拮抗剂或其药用盐及药用载体。
特别有效的CGRP受体拮抗剂为(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺三水合物:
其可通过在以下文献中所述的操作来制备:MerckSharp&DohmeCorp.的在2012年5月18日出版的国际公开文本WO2012/064910,其在本申请中也将称为“化合物I”。(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺也通过其通用名即Ubrogepant被知晓。化合物I为BCS第4类化合物,其具有低的溶解性及低的渗透性(16.6×10-6cm/s)。在本发明的液体药物组合物中,化合物I保留在溶液中且在用唾液稀释后不会立即析出。
本发明的液体药物组合物也可含有一种或多种额外的制剂成分,其可选自在药物制剂领域中已知的很多种赋形剂。根据液体药物组合物的所需性质,可单独或组合选择任何数目的成分,这取决于它们在制备液体药物组合物中的已知用途。这样的成分包括但不限于矫味剂、矫味增强剂、甜味剂、防腐剂和着色剂。
本申请使用的术语“液体药物组合物”意在涵盖包含CGRP受体拮抗剂的溶液。
本发明的药物组合物为包含CGRP受体拮抗剂和药用载体的液体药物溶液。
本发明的药物组合物为液体药物溶液,其包含(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺或其药用盐及药用载体,其中所述载体的体积小于10mL。在本发明的一个实施方案中,所述液体药物溶液包含无定形形式的(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺。在本发明的另一个实施方案中,所述液体药物溶液包含无水形式的(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺。在本发明的另一个实施方案中,所述液体药物溶液包含水合物形式的(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺。在本发明的一个方面,本发明的药物组合物为液体药物溶液,其包含(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺三水合物。
在本发明的一个实施方案中,所述药用载体包括亲水性载体和水溶性表面活性剂或水溶性表面活性剂的混合物。
在本发明的一个实施方案中,所述亲水性载体包括水、二醇、二醇酯及其组合。
在本发明的一个实施方案中,二醇选自丙二醇、PEG和甘油;二醇酯选自有机酸的甘油酯和丙二醇酯或其混合物。在本发明的一个方面,二醇选自丙二醇、PEG-400、甘油或其混合物。在本发明的一个方面,所述有机酸具有两个或三个碳原子。
在本发明的一个实施方案中,二醇酯包括甘油三乙酸酯、柠檬酸三乙酯或其混合物。
在本发明的一个实施方案中,所述水溶性表面活性剂选自VitE-TPGS、泊洛沙姆、吐温20、吐温80、司盘20及其组合。在本发明的一个方面,所述表面活性剂为VitE-TPGS。在本发明的一个方面,所述表面活性剂为泊洛沙姆。在本发明的另一个方面,所述表面活性剂为泊洛沙姆与吐温20。在本发明的另一个方面,所述表面活性剂为泊洛沙姆与吐温80。在本发明的另一个方面,所述表面活性剂为泊洛沙姆与司盘20。在本发明的一个亚方面,所述泊洛沙姆为泊洛沙姆407。在本发明的另一个方面,所述表面活性剂为VitE-TPGS与吐温20。在本发明的另一个方面,所述表面活性剂为VitE-TPGS与吐温80。在本发明的另一个方面,所述表面活性剂为VitE-TPGS与司盘20。
在本发明的一个实施方案中,所述水溶性表面活性剂按所述组合物的重量计以约0.1%至15.0%的量存在。在本发明的一个方面,所述水溶性表面活性剂按所述组合物的重量计以2.5%至10%的量存在。适当的水溶性表面活性剂为VitE-TPGS。另一种适当的水溶性表面活性剂为泊洛沙姆407。
在本发明的一个实施方案中,所述CGRP受体拮抗剂按所述组合物的重量计以约0.01%至3.0%的量存在。在本发明的一个方面,所述CGRP受体拮抗剂按所述组合物的重量计以0.25%至2.0%的量存在。作为本发明的实例,所述CGRP受体拮抗剂为(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺三水合物或其盐。
在本发明的一个实施方案中,所述载体的体积小于5mL。
在本发明的一个实施方案中,包含一种或多种药用赋形剂,其选自防成核聚合物、抗氧化剂(诸如抗坏血酸)、螯合剂(诸如乙二胺四乙酸(EDTA))、酸化剂、氯化钠、着色剂(诸如水溶性和有机可溶性染料)、甜味剂、矫味剂或其混合物。
在本发明的一个实施方案中,所述防成核聚合物选自聚维酮和Kollidone-VA64。
在本发明的一个实施方案中,所述酸化剂选自柠檬酸、苹果酸、乳酸、柠檬酸钠及其组合。
在本发明的一个实施方案中,所述矫味剂选自薄荷、欧薄荷、浆果、樱桃、薄荷醇和氯化钠矫味剂及其组合。
在本发明的一个实施方案中,所述甜味剂选自糖、三氯蔗糖、阿司帕坦、乙酰舒泛、纽甜及其组合。在本发明的一个方面,所述甜味剂选自三氯蔗糖、阿司帕坦、乙酰舒泛、纽甜及其组合。在本发明的一个亚方面,所述甜味剂为三氯蔗糖。
本发明的实例为液体药物组合物,其包含(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺、丙二醇、PEG-400、水、VitE-TPGS、聚维酮、三氯蔗糖、薄荷醇和欧薄荷矫味剂。本发明的另一个实例为液体药物组合物,其包含(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺、丙二醇、PEG-400、水、VitE-TPGS、聚维酮、三氯蔗糖、薄荷醇、欧薄荷或薄荷矫味剂、酸化剂和氯化钠。
本发明的液体药物组合物在室温是稳定的。具体地,所述液体药物组合物在室温即在约25℃(±2℃)至40℃(±2℃)的范围内具有良好的物理和化学稳定性。
本发明的液体药物组合物在室温具有低的粘度(~0.065Pa.s)。理想的是,使液体药物组合物具有低的粘度,其可快速离开容器。在本发明的一个实施方案中,所述液体药物组合物在1-10秒内离开容器。在本发明的一个方面,所述液体药物组合物在1-5秒内离开容器。
本发明的液体药物组合物所包含的赋形剂的水平适于每天施用且适于按需允许单一重复给药。
本发明的液体药物组合物适于装填到多剂量或单位剂量包装中而不产生脱色或降解。
本发明包括制备(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺三水合物的液体药物组合物的方法,其包括以下步骤:
(i)在室温或在较高的温度(约40℃)将水溶性表面活性剂溶解在亲水性载体中直到通过连续搅拌形成均匀的溶液;
(ii)将额外的赋形剂诸如矫味剂溶解在来自步骤(i)的溶液中;
(iii)将水溶性赋形剂(诸如防成核聚合物、甜味剂、矫味剂)溶解在水中;
(iv)通过连续搅拌使来自步骤(iii)的溶液与步骤(ii)的溶液混合;
(v)在室温或40℃通过连续搅拌将(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺三水合物溶解在步骤(iv)的溶液中直到形成均匀的溶液;
(vi)将一种或多种赋形剂溶解在来自步骤(v)的溶液中。
本发明的液体药物组合物可用于治疗性或预防性处置与CGRP功能化相关的病症。这样的病症包括:偏头痛和丛集性头痛;慢性紧张型头痛;慢性疼痛;神经源性炎症和炎性疼痛;眼部疼痛;牙痛;非胰岛素依赖性糖尿病;血管病症;炎症;关节炎;支气管高反应性;哮喘;休克;败血病;鸦片戒断综合征;吗啡耐受;男性和女性中的热潮红;变应性皮炎;银屑病;脑炎、脑外伤、局部缺血、中风、癫痫和神经变性疾病;皮肤疾病;神经性皮肤发红、皮肤发红和红斑;耳鸣;肥胖;炎性肠病;肠易激综合征;和膀胱炎。在本发明的一个方面,本发明的液体药物组合物可用于急性处置或预防性处置头痛,包括偏头痛和丛集性头痛。
以下实施例出于示例说明本发明的目的而给出且不应该被理解为限制本发明的范围。
实施例1
具有(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[B]吡啶-6,3’-吡咯并[2,3-B]吡啶]-3-甲酰胺三水合物(化合物I)的口服液体制剂
如上提供的口服液体制剂如下制备:
1)在玻璃瓶中将VitE-TPGS(形式为<4mm的小片)加到丙二醇中并将混合物温热至约40℃(使用搅拌棒及磁力搅拌器/加热器)。
2)搅拌直到VitE-TPGS完全溶解并得到澄清溶液(~<1h)。
3)停止加热。
4)将PEG-400加到“VitE-TPGS-丙二醇”溶液中并搅拌混合物(溶液将略微浑浊)(~5min)。
5)将额外的赋形剂诸如薄荷醇溶解在来自步骤(4)的溶液中。
6)在烧杯中将PVP加到“水”中并搅拌溶解(~<30min)。
7)加入甜味剂、盐、酸化剂并搅拌溶解(~10min)。
8)将“PVP-甜味剂-盐-酸化剂溶液”加到“VitE-TPGS-PG-PEG-400溶液”中并搅拌混合(~<10min)。
9)将化合物I加到上述溶液(步骤8)中并搅拌溶解(将溶液温热至约~40℃以较快溶解)(~10min)。溶液应该是澄清的。
10)加入矫味剂并搅拌混合(~5min)。
实施例2
(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[B]吡啶-6,3’-吡咯并[2,3-B]吡啶]-3-甲酰胺三水合物(化合物I)口服液体制剂在狗中的药物代谢动力学
为了评价溶液体积对暴露的作用,在狗中测试了两种制剂;每种溶液具有相同剂量的化合物I,但是溶液体积是不同的。经由注射器将口服溶液制剂递送至狗的咽喉后部(以刺激吞咽小体积的液体溶液)。没有用口服溶液制剂进行淋洗。对于溶液,使用0.75mL的高药物浓度溶液及1.5mL的低药物浓度溶液。对于PEG参比溶液,给予10mg剂量/20mL媒介物,随后给予15mL水。
来自禁食的用五肽胃泌素预处理的比格犬中的低体积口服PVE溶液的化合物I在狗中的PK
在狗中,两种口服溶液与先前得到的PEG400溶液数据相比都具有略微较好的暴露。
口服溶液
PEG400溶液:PEG400/Orasweet/水70%/15%/15%(给予10mg剂量/20mL媒介物,随后给予15mL水)。PEG400溶液由于PEG400的量是高的而不适于长期使用。其仅适合在早期临床研究中作为单一剂量。
实施例3
(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[B]吡啶-6,3’-吡咯并[2,3-B]吡啶]-3-甲酰胺三水合物(化合物I)在稀释后在人工唾液中的析出
将化合物I口服液体制剂的样品用pH为6.2的人工唾液以1:1或1:4的比例稀释。人工唾液包含:KH2PO4(12mM)、NaCl(40mM)、CaCl2(1.5mM)和NaOH至pH6.2(参考:RitschelandThomson,MethodsandfindingsinExperimentalandClinicalPharmacology,%,511-525,1983)。使用400RPM的磁力搅拌。在不同时间点采集样品以确定稀释后的潜在析出动力学。在5分钟时间点使用0.45μm滤器进行离心过滤,且在更长的时间点使用1μm过滤和超速离心(80kRPM,25℃,15分钟,9/9加速/减速)。将样品用50/50ACN/水稀释以试图与分析用标准浓度(0.1mg/mL)匹配并用HPLC进行分析。所使用的LC条件如下:65%0.1%H3PO4/35%CAN等度法,ChromolithSpeedRODRP-18e50×4.6mm柱,UV在210nm,40℃柱温,3mL/min流速,及10μL注射体积。
析出总结:制剂A(描述在实施例1中)在用pH为6.2的唾液以1:1和1:4稀释后的药物浓度
当将溶液A以1:1稀释时,化合物I没有析出,且浓度保持在预期水平(几乎为原始浓度的一半)。
当将溶液A以1:4稀释时,药物浓度保持在预期水平(约为原始浓度的1/5)约30分钟,然后开始缓慢析出。
这些结果表明溶液A当在口中被唾液稀释后对析出具有抗性。
实施例4
(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[B]吡啶-6,3’-吡咯并[2,3-B]吡啶]-3-甲酰胺三水合物(化合物I)口服液体制剂的粘度
为了测量粘度,使用带有TRIOS软件的TAInstrumentsARESG2应变控制流变仪。由于样品的粘度是低的而使用双壁结构。所有液体都表现为在5-20s-1之间的牛顿流体。所选择的等温保持时间为5分钟,认为其达到平衡。如下所示,所测试的三种制剂都显示出低粘度(<0.065)。
液体制剂在25℃和10℃的粘度
*该值应该与安慰剂的粘度相似。
Claims (20)
1.一种液体药物组合物,其包含(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺或其药用盐和药用载体,其中所述载体的体积小于10mL。
2.权利要求1的液体药物组合物,其包含(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺三水合物。
3.权利要求1的液体药物组合物,其中所述载体包括:亲水性载体;和水溶性表面活性剂或水溶性表面活性剂的混合物。
4.权利要求3的液体药物组合物,其中所述亲水性载体包括水、二醇、二醇酯或其组合。
5.权利要求4的液体药物组合物,其包含:选自丙二醇和PEG的二醇;和选自有机酸的甘油酯、丙二醇酯或其混合物的二醇酯。
6.权利要求5的液体药物组合物,其中二醇选自丙二醇、PEG-400、甘油及其混合物。
7.权利要求5的液体药物组合物,其中二醇酯选自甘油三乙酸酯、柠檬酸三乙酯及其混合物。
8.权利要求3的液体药物组合物,其中所述水溶性表面活性剂选自VitE-TPGS、泊洛沙姆、吐温20、吐温80和司盘20及其组合。
9.权利要求8的液体药物组合物,其中所述水溶性表面活性剂选自VitE-TPGS、泊洛沙姆、泊洛沙姆与吐温20、泊洛沙姆与吐温80、泊洛沙姆与司盘20、VitE-TPGS与吐温20、VitE-TPGS与吐温80及VitE-TPGS与司盘20。
10.权利要求3的液体药物组合物,其中所述水溶性表面活性剂按所述组合物的重量计以约0.1%至15.0%的量存在。
11.权利要求10的液体药物组合物,其中所述水溶性表面活性剂按所述组合物的重量计以2.5%至10%的量存在。
12.权利要求11的液体药物组合物,其中所述水溶性表面活性剂为VitE-TPGS或泊洛沙姆。
13.权利要求1的液体药物组合物,其中(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺或其盐按所述组合物的重量计以约0.01%至3.0%的量存在。
14.权利要求13的液体药物组合物,其中(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2’-氧代-1’,2’,5,7-四氢螺[环戊并[b]吡啶-6,3’-吡咯并[2,3-b]吡啶]-3-甲酰胺或其盐按所述组合物的重量计以0.25%至2.0%的量存在。
15.权利要求1的液体药物组合物,其中所述载体的体积小于5mL。
16.权利要求1的液体药物组合物,其还包含一种或多种选自以下的药用赋形剂:防成核聚合物、抗氧化剂、螯合剂、酸化剂、氯化钠、着色剂、甜味剂和矫味剂。
17.权利要求1的液体药物组合物,其包含丙二醇、PEG-400、水、VitE-TPGS、聚维酮、三氯蔗糖、薄荷醇及薄荷或欧薄荷矫味剂。
18.权利要求17的液体药物组合物,其还包含酸化剂。
19.治疗偏头痛的方法,其通过给予权利要求1的液体药物组合物。
20.治疗偏头痛的方法,其通过给予权利要求17的液体药物组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011381004.0A CN112545981A (zh) | 2013-09-16 | 2014-09-11 | 用于cgrp受体拮抗剂的制剂 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361878183P | 2013-09-16 | 2013-09-16 | |
US61/878,183 | 2013-09-16 | ||
PCT/US2014/055132 WO2015038736A2 (en) | 2013-09-16 | 2014-09-11 | Formulations for cgrp receptor antagonists |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011381004.0A Division CN112545981A (zh) | 2013-09-16 | 2014-09-11 | 用于cgrp受体拮抗剂的制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105531275A true CN105531275A (zh) | 2016-04-27 |
CN105531275B CN105531275B (zh) | 2020-12-18 |
Family
ID=52666511
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480050553.6A Expired - Fee Related CN105531275B (zh) | 2013-09-16 | 2014-09-11 | 用于cgrp受体拮抗剂的制剂 |
CN202011381004.0A Pending CN112545981A (zh) | 2013-09-16 | 2014-09-11 | 用于cgrp受体拮抗剂的制剂 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011381004.0A Pending CN112545981A (zh) | 2013-09-16 | 2014-09-11 | 用于cgrp受体拮抗剂的制剂 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20160220552A1 (zh) |
EP (2) | EP3915561A1 (zh) |
JP (1) | JP6612234B2 (zh) |
KR (3) | KR20210153745A (zh) |
CN (2) | CN105531275B (zh) |
AU (1) | AU2014318741B2 (zh) |
BR (1) | BR112016005589B8 (zh) |
CA (1) | CA2923426A1 (zh) |
IL (1) | IL244356B (zh) |
MX (1) | MX2016003394A (zh) |
RU (1) | RU2690006C2 (zh) |
SA (1) | SA516370737B1 (zh) |
WO (1) | WO2015038736A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI522355B (zh) * | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑 |
WO2015119848A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
US20210128724A1 (en) * | 2019-07-05 | 2021-05-06 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders |
WO2022140537A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004004783A1 (en) * | 2002-07-03 | 2004-01-15 | Biomedica Foscama Industria Chimico-Farmaceutica S.P.A. | Liquid compositions for the oral administration of lorazepam |
WO2008030524A2 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
US20100112050A1 (en) * | 2008-11-03 | 2010-05-06 | Je Phil Ryoo | Dosage Form For Insertion Into The Mouth |
US20120122899A1 (en) * | 2010-11-12 | 2012-05-17 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide azaindane cgrp receptor antagonists |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9815801D0 (en) * | 1998-07-21 | 1998-09-16 | Merck & Co Inc | Liquid polymeric compositions for controlled released bioactive substances |
ES2241269T3 (es) * | 1998-03-19 | 2005-10-16 | MERCK & CO., INC. | Sulfuropentafluorofenilpirazoles para el control de infestaciones por ectoparasitos. |
US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
-
2014
- 2014-09-11 MX MX2016003394A patent/MX2016003394A/es unknown
- 2014-09-11 KR KR1020217040059A patent/KR20210153745A/ko not_active Application Discontinuation
- 2014-09-11 CN CN201480050553.6A patent/CN105531275B/zh not_active Expired - Fee Related
- 2014-09-11 US US15/021,471 patent/US20160220552A1/en not_active Abandoned
- 2014-09-11 WO PCT/US2014/055132 patent/WO2015038736A2/en active Application Filing
- 2014-09-11 RU RU2016114537A patent/RU2690006C2/ru active
- 2014-09-11 JP JP2016542091A patent/JP6612234B2/ja active Active
- 2014-09-11 CN CN202011381004.0A patent/CN112545981A/zh active Pending
- 2014-09-11 CA CA2923426A patent/CA2923426A1/en active Pending
- 2014-09-11 BR BR112016005589A patent/BR112016005589B8/pt active IP Right Grant
- 2014-09-11 EP EP21171525.5A patent/EP3915561A1/en active Pending
- 2014-09-11 EP EP14844555.4A patent/EP3046923A4/en not_active Withdrawn
- 2014-09-11 KR KR1020167006505A patent/KR102337994B1/ko active IP Right Grant
- 2014-09-11 KR KR1020227025748A patent/KR20220108207A/ko not_active Application Discontinuation
- 2014-09-11 AU AU2014318741A patent/AU2014318741B2/en active Active
-
2016
- 2016-02-29 IL IL244356A patent/IL244356B/en active IP Right Grant
- 2016-03-14 SA SA516370737A patent/SA516370737B1/ar unknown
-
2018
- 2018-09-10 US US16/125,924 patent/US20190070161A1/en not_active Abandoned
-
2020
- 2020-12-07 US US17/114,169 patent/US20210330660A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004004783A1 (en) * | 2002-07-03 | 2004-01-15 | Biomedica Foscama Industria Chimico-Farmaceutica S.P.A. | Liquid compositions for the oral administration of lorazepam |
WO2008030524A2 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
US20100112050A1 (en) * | 2008-11-03 | 2010-05-06 | Je Phil Ryoo | Dosage Form For Insertion Into The Mouth |
US20120122899A1 (en) * | 2010-11-12 | 2012-05-17 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide azaindane cgrp receptor antagonists |
Also Published As
Publication number | Publication date |
---|---|
MX2016003394A (es) | 2016-10-28 |
CA2923426A1 (en) | 2015-03-19 |
EP3915561A1 (en) | 2021-12-01 |
AU2014318741B2 (en) | 2018-12-06 |
US20190070161A1 (en) | 2019-03-07 |
RU2016114537A3 (zh) | 2018-07-04 |
EP3046923A2 (en) | 2016-07-27 |
RU2016114537A (ru) | 2017-10-23 |
WO2015038736A2 (en) | 2015-03-19 |
RU2690006C2 (ru) | 2019-05-30 |
KR20160055149A (ko) | 2016-05-17 |
SA516370737B1 (ar) | 2021-05-27 |
US20210330660A1 (en) | 2021-10-28 |
KR20220108207A (ko) | 2022-08-02 |
IL244356A0 (en) | 2016-04-21 |
KR20210153745A (ko) | 2021-12-17 |
BR112016005589B1 (pt) | 2022-12-06 |
JP6612234B2 (ja) | 2019-11-27 |
KR102337994B1 (ko) | 2021-12-13 |
BR112016005589A8 (pt) | 2018-02-06 |
EP3046923A4 (en) | 2017-03-22 |
IL244356B (en) | 2020-09-30 |
NZ717327A (en) | 2021-10-29 |
BR112016005589B8 (pt) | 2023-04-18 |
CN112545981A (zh) | 2021-03-26 |
CN105531275B (zh) | 2020-12-18 |
AU2014318741A1 (en) | 2016-03-10 |
JP2016530316A (ja) | 2016-09-29 |
US20160220552A1 (en) | 2016-08-04 |
WO2015038736A3 (en) | 2015-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI230079B (en) | Solid pharmaceutical dispersions with enhanced bioavailability | |
US20210330660A1 (en) | Formulations for cgrp receptor antagonists | |
JP6226966B2 (ja) | デガレリクスの製造 | |
NL2023661B1 (en) | Pharmaceutical Eutectic Salt Formulation | |
UA125514C2 (uk) | Склади фульвестранту і способи їх застосування | |
DE69928500T2 (de) | Pharmazeutische zusammensetzung enthaltend den phospholipase inhibitor natrium-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1 h-indol-4-yl]oxy]acetat | |
DK2793863T3 (en) | PROCEDURE FOR THE PREPARATION OF AMORPH PRECIPTATED PROTEIN PARTICLES | |
TR201809354T4 (tr) | 5 alfa androstan (alkil) 3 beta,5,6 beta triol enjeksiyonu ve Bunun hazırlanmasına yönelik yöntem. | |
RU2084226C1 (ru) | Композиция, обладающая противоопухолевым действием | |
JP2001316265A (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
KR102113822B1 (ko) | 주사용 항생제 제제 및 그의 이용 방법 | |
NZ717327B2 (en) | Formulations for cgrp receptor antagonists | |
CN104511012B (zh) | 一种环孢素口服溶液 | |
EP2874623B1 (en) | Injectable antibiotic formulations and their methods of use | |
PATEL et al. | International Journal of Current Pharmaceutical Research | |
EP3589325A1 (fr) | Formulation pharmaceutique pour l'administration par voie bucco-gingivale de paracetamol | |
NZ613240B2 (en) | Injectable antibiotic formulations and their methods of use | |
NZ629041A (en) | Injectable antibiotic formulations and their methods of use | |
CN103040733A (zh) | 一种含有盐酸纳美芬化合物的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201218 Termination date: 20210911 |
|
CF01 | Termination of patent right due to non-payment of annual fee |